Portal de Periódicos da CAPES

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations

2015; Wiley; Volume: 169; Issue: 6 Linguagem: Inglês

10.1111/bjh.13382

1365-2141

Cindy Varga, Wanling Xie, Jacob P. Laubach, Irene M. Ghobrial, Elizabeth O’Donnell, Matthew Weinstock, Claudia E. Paba‐Prada, Diane Warren, Michelle E. Maglio, Robert Schlossman, Nikhil C. Munshi, Noopur Raje, Edie Weller, Kenneth C. Anderson, Constantine S. Mitsiades, Paul G. Richardson,

Peptidase Inhibition and Analysis

Summary Proteasome inhibitors ( PI ) and immunomodulatory agents ( IMID s) have improved the overall survival (OS) of patients with multiple myeloma ( MM ), but concerns have been raised about increased incidence of extramedullary disease ( EMD ) after the combined use of PI s and IMID s for upfront therapy. We evaluated whether the addition of lenalidomide to bortezomib‐based front‐line regimens precipitated earlier development of EMD . We reviewed the charts of 117 MM patients (median follow‐up from diagnosis 6·1 years; range 0·1–10·2 years) enrolled in eight clinical trials of first‐line treatment with bortezomib‐based regimens, with or without lenalidomide. We assessed development of EMD as extraosseous (distant from bone) or osseous (originating from bone) plasmacytomas. The primary endpoint was time from diagnosis until development of EMD , based on imaging, biopsy and/or physical examination. Any form of EMD at progression was observed in 40 (34·2%) patients, including 21 (18%) osseous, 8 (7%) extraosseous and 11 (9%) both osseous and extraosseous. Median OS was 0·9 years (range 0·1–4·8 years) after extraosseous EMD development. Sensitivity analyses with follow‐up times truncated at 5 years detected no statistically significant difference in rates of any EMD form between the two groups ( P > 0·2 for each comparison). Therefore, we observed no evidence that bortezomib–lenalidomide‐based front‐line therapy precipitates earlier EMD .